Erratum: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy (Oncotarget (2018) 9 (5216-5232) DOI: 10.18632/oncotarget.23749)

Caroline M. Robb, Smit Kour, Jacob I. Contreras, Ekta Agarwal, Carter J. Barger, Sandeep Rana, Yogesh Sonawane, Beth K. Neilsen, Margaret Taylor, Smitha Kizhake, Rhishikesh N. Thakare, Sanjib Chowdhury, Jing Wang, Jennifer D. Black, Michael A. Hollingsworth, Michael G. Brattain, Amarnath Natarajan

Research output: Contribution to journalComment/debatepeer-review

Abstract

This article has been corrected: The pRb blots in HCT116 and HT29 in Figure 3B were inadvertently duplicated during the assembly of the figure. The corrected Figure 3 is shown below. The authors declare that these corrections do not change the results or the conclusions of this paper. (Figure Presented).

Original languageEnglish (US)
Pages (from-to)2462-2463
Number of pages2
JournalOncotarget
Volume11
Issue number25
DOIs
StatePublished - Jun 23 2020

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Erratum: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy (Oncotarget (2018) 9 (5216-5232) DOI: 10.18632/oncotarget.23749)'. Together they form a unique fingerprint.

Cite this